-33%

est. 2Y upside i

HealthcareSeries B

Rank

#743

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: High

Archy presents a strong upside opportunity driven by its impressive ~300% YoY growth and a compelling AI-driven, all-in-one cloud platform that addresses a significant pain point in the dental industry.

Last updated: March 10, 2026

Bull (30%)+250%

Archy continues its rapid ~300% YoY growth, expanding its market penetration beyond 45 states and internationally. Its AI-driven platform and native mobile app solidify its 'strong moat' against legacy systems like Dentrix and Eaglesoft, driving significant customer acquisition and retention. Revenue could reach $50M-$70M ARR within 2 years, justifying a premium 10-14x multiple for an AI-driven HealthTech SaaS, leading to a valuation of $700M.

Base (50%)+75%

Archy maintains strong growth (e.g., 100-150% YoY) but faces increased competition from incumbents launching their own cloud/AI solutions or aggressive pricing. It successfully captures a significant share of the $1.0B SAM but doesn't fully displace the largest incumbents. Revenue reaches $25M-$35M ARR, justifying a 10x-12x multiple, leading to a valuation of $350M.

Bear (20%)-60%

Growth slows significantly due to aggressive competitive responses from incumbents like Henry Schein (Dentrix/Eaglesoft) or new well-funded entrants. Regulatory hurdles prove more challenging than anticipated, or the AI features fail to deliver the promised 80 hours of savings, leading to slower adoption. Revenue stalls at $10M-$15M ARR, and a down round or flat round with a compressed multiple (e.g., 5-8x) leads to a valuation of $80M, severely impacting common stock value given the $47M in liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Funding Intensity

24%

Investors hold $47M in liquidation preferences. In an exit at or below the current $200M valuation, common stock holders would receive proceeds only after these preferences are paid out. For example, at an $80M exit, common shareholders would split $33M.

Dilution Risk

moderate

As a Series B company with $47M raised, it's likely they will need at least one more significant funding round (Series C/D) before an IPO or large acquisition, which will lead to further dilution for existing equity holders.

Secondary Liquidity

none

There is no information suggesting active secondary markets or tender offers for Archy's equity.

Engineering — 6 roles

Sales — 4 roles

View all 10 open roles at Archy →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Archy's data — designed to show you've done your homework.

  • 1

    “How is Archy planning to continue differentiating its AI capabilities and integrated platform against established incumbents like Dentrix (Henry Schein) and emerging cloud competitors like CareStack, especially as they inevitably enhance their own cloud and AI offerings?”

  • 2

    “With a $200M valuation and ~300% YoY growth, what is Archy's current ARR, and what are the key milestones (e.g., ARR targets, customer count, market share) the company aims to achieve over the next 18-24 months to justify its next funding round or a potential exit?”

  • 3

    “Given the Series B funding and the 23.5% funding intensity, how does Archy envision the path to a liquidity event for employees, and what is the company's philosophy on managing dilution and potential secondary liquidity opportunities in the future?”

Community

Valuation Sentiment

Our model estimates -33% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.